https://wikimd.org/index.php?action=history&feed=atom&title=Lifitegrast_ophthalmic_solutionLifitegrast ophthalmic solution - Revision history2026-04-27T05:01:49ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Lifitegrast_ophthalmic_solution&diff=4973323&oldid=prevPrab at 01:18, 17 October 20232023-10-17T01:18:40Z<p></p>
<p><b>New page</b></p><div>=='''What is Lifitegrast ophthalmic solution?'''==<br />
lifitegrast ophthalmic solution is a lymphocyte function-associated antigen-1 (LFA-1) antagonist supplied as a sterile, clear, colorless to slightly brownish-yellow colored, isotonic solution of lifitegrast with a pH of 7.0-8.0, and an osmolality range of 200-330 mOsmol/kg. The chemical name for lifitegrast is (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid. The molecular formula of lifitegrast is C29H24Cl2N2O7S and its molecular weight is 615.5 g/mol. <br />
<br />
=='''What are the uses of this medicine?'''==<br />
It is indicated for the treatment of the signs and symptoms of dry eye disease (DED).<br />
<br />
=='''How does this medicine work?'''==<br />
Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in DED is not known.<br />
<br />
=='''Who Should Not Use this medicine?'''==<br />
It is contraindicated in patients with known hypersensitivity to lifitegrast .<br />
<br />
=='''Is this medicine FDA approved?'''==<br />
It is approved by US FDA on Jul 12, 2016.<br />
<br />
=='''What are the brand names and dosage forms of this medicine?'''==<br />
* Brand name: [[Xiidra]]; NDC codes: 0078-0911-05, 0078-0911-12, 0078-0911-94, 0078-0911-95.<br />
* Ophthalmic solution containing lifitegrast 50 mg/mL (5%).<br />
<br />
=='''How should this medicine be used?'''==<br />
Instill one drop of Xiidra twice daily (approximately 12 hours apart) into each eye using a single-use container. Discard the single-use container immediately after using in each eye.<br />
<br />
==''' What special precautions should I follow?'''==<br />
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.<br />
<br />
=='''What side effects can this medication cause?'''==<br />
* Hypersensitivity<br />
<br />
=='''What to do in case of emergency/overdose?'''==<br />
* {{overdose}}<br />
<br />
=='''Can this medicine be used in pregnancy?'''==<br />
There are no available data on Xiidra use in pregnant women to inform any drug-associated risks.<br />
<br />
=='''Can this medicine be used in children?'''==<br />
Safety and efficacy in pediatric patients below the age of 17 years have not been established.<br />
<br />
=='''What should I know about storage and disposal of this medication?'''==<br />
Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the original foil pouch.<br />
<br />
{{coststubd}}<br />
{{pharma-stub}}<br />
{{Protein and peptide receptor modulators}}<br />
<br />
[[Category:Ophthalmology drugs]]<br />
[[Category:Amino acids]]<br />
[[Category:Benzosulfones]]<br />
[[Category:Benzamides]]</div>Prab